Holen Sie sich die Stockscreener-App
2.77
9.06%
0.23
Handel nachbörslich:
2.77
Schlusskurs vom Vortag:
$2.54
Offen:
$2.6
24-Stunden-Volumen:
1.68M
Relative Volume:
1.44
Marktkapitalisierung:
$157.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-82.44M
KGV:
-1.4734
EPS:
-1.88
Netto-Cashflow:
$-66.75M
1W Leistung:
+2.97%
1M Leistung:
-3.48%
6M Leistung:
+18.38%
1J Leistung:
-48.32%
1-Tages-Spanne:
$2.5601
$2.79
1-Wochen-Bereich:
$2.22
$2.79
52-Wochen-Spanne:
$1.195
$6.75
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Firmenname
Black Diamond Therapeutics Inc
Sektor
Branche
Telefon
617-417-5868
Adresse
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Vergleichen Sie BDTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.77 | 144.43M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-01 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-31 | Eingeleitet | Raymond James | Outperform |
| 2023-07-14 | Eingeleitet | Piper Sandler | Overweight |
| 2023-06-30 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-03-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-03-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Hold |
| 2021-01-07 | Eingeleitet | Wedbush | Outperform |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-02-24 | Eingeleitet | Cowen | Outperform |
| 2020-02-24 | Eingeleitet | JP Morgan | Overweight |
| 2020-02-24 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Black Diamond Therapeutics Inc Aktie (BDTX) Neueste Nachrichten
What moving averages say about Black Diamond Therapeutics Inc.Earnings Risk Report & Real-Time Volume Spike Alerts - Newser
Will Breakout in Black Diamond Therapeutics Inc. Sustain Through Next Week2025 Institutional Moves & Consistent Profit Alerts - metal.it
Machine Learning Models Forecast Black Diamond Therapeutics Inc. Uptick2025 Investor Takeaways & Precise Buy Zone Identification - metal.it
Chart based analysis of Black Diamond Therapeutics Inc. trendsBuy Zone Strategy with Pattern Recognition - Newser
Top Risks to Consider Before Buying Black Diamond Therapeutics Inc. StockInstitutional Holding Behavior Pattern Analysis - Newser
Black Diamond Therapeutics Reports Strong Financial Turnaround - TipRanks
Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows Promise - MSN
What makes Black Diamond Therapeutics Inc. stock price move sharplyDaily Pattern Analysis with Return Forecast - Newser
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Cuts Target Price to $10 - 富途牛牛
H.C. Wainwright lowers Black Diamond Therapeutics stock price target on delayed launch - Investing.com Canada
Published on: 2025-08-11 06:28:53 - Newser
Black Diamond:HC Wainwright lowers PT to $10 from $12, maintains Buy rating. - AInvest
News impact scoring models applied to Black Diamond Therapeutics Inc.Fundamental Forecast for Undervalued Stocks - Newser
When is the best time to exit Black Diamond Therapeutics Inc.Momentum Trend Signal Weekly Recap Summary - Newser
Is Black Diamond Therapeutics Inc. a Top Dividend Stock to Watch in 2025Free Weekly Hot Picks With Buy Confidence - Newser
Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - Yahoo Finance
Black Diamond Therapeutics Reports Q2 Earnings with $45.98M Net Income and $70M Upfront Payment from Servier Agreement - AInvest
Black Diamond Therapeutics Maintains Buy Rating with $11 Price Target - AInvest
Historical volatility pattern of Black Diamond Therapeutics Inc. visualizedFree Daily Chart Pattern Stock Forecast - Newser
Black Diamond Therapeutics shares rise 1.75% premarket after reporting a narrower Q2 net loss and exploring partnerships for silevertinib development. - AInvest
Black Diamond Therapeutics Slims Losses And Stays Flush With Cash - Finimize
Black Diamond (BDTX) Q2 Loss Narrows 47% - AOL.com
Black Diamond Therapeutics: Navigating Turbulent Waters with Strategic Precision - AInvest
Black Diamond Therapeutics Cuts Losses And Eyes Silevertinib Growth - Finimize
Black Diamond: Q2 Earnings Snapshot - The Washington Post
Black Diamond Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Black Diamond Therapeutics Reports Q2 2025 Financial Results: Net Loss Down 47%, Cash Reserves Reach $142.8 Million - AInvest
Black Diamond Therapeutics Q2 Loss Narrower Than ExpectedNews and Statistics - IndexBox
Black Diamond Therapeutics Q2 eps $-0.19 - MarketScreener
Black Diamond (BDTX) Q2 Loss Narrows 47% - The Motley Fool
Black Diamond Therapeutics Completes Enrollment in Phase 2 Trial of Silevertinib for Non-Classical EGFRm NSCLC - Quiver Quantitative
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Black Diamond Therapeutics, Inc. SEC 10-Q Report - TradingView
Will Black Diamond Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsFree Daily Top Performing Stock Insights - Newser
Why Black Diamond Therapeutics Inc. stock attracts strong analyst attentionFree Investment Playbook for Growing Markets - Newser
Price action breakdown for Black Diamond Therapeutics Inc.Daily Profit Watch With Forecast Confidence - Newser
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Rating of “Buy” by Brokerages - Defense World
Is Black Diamond Therapeutics Inc. stock ready for a breakoutHigh Return Idea With Technical Filter - Newser
Using portfolio simulators with Black Diamond Therapeutics Inc. includedReal-Time Entry Forecast with Accuracy Metrics - Newser
Has Black Diamond Therapeutics Inc. formed a bullish divergenceFree AI Screening for Swing Trade Picks - Newser
Finanzdaten der Black Diamond Therapeutics Inc-Aktie (BDTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):